Mallinckrodt announces data at EASL on Terlivaz as treatment for HRS

Ireland-headquartered Mallinckrodt (NYSE: MNK) has released new data on Terlivaz (terlipressin) for injection in patients with hepatorenal syndrome (HRS) with rapid reduction in kidney function at the European Association for the Study of Liver (EASL) congress currently taking place in Milan, Italy.

The posters include a retrospective chart review that examined the potential relationship of serum creatinine (SCr) levels and treatment outcomes in support of earlier diagnosis; data analyzing clinical response to Tirlivaz in HRS patients with a mean arterial pressure (MAP) of <65 mm Hg; and the effect of Terlivaz on renal function among patients with alcohol-associated hepatitis (AAH) and hepatorenal syndrome-acute kidney injury (HRS-AKI) who had acute-on-chronic liver failure (ACLF) grades 0–2.

Mallinckrodt noted that Terlivaz is the first and only US Food and Drug Administration (FDA)-approved product indicated to improve kidney function in adults with HRS with rapid reduction in kidney function, an acute and life-threatening condition requiring hospitalization. HRS involving rapid reduction in kidney function is estimated to affect more than 42,000 Americans annually and rates of hospitalizations are increasing. Currently, Terlivaz is only approved in the USA.